We are live on ! Find out more
TGV

TRV GP V Portfolio holdings

AUM $498M
1-Year Est. Return 267.53%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+267.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$498M
AUM Growth
+$97.2M
Cap. Flow
-$31.4M
Cap. Flow %
-6.3%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$31.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPP
1
Rapport Therapeutics
RAPP
$2.11B
$262M 52.53%
6,280,525
-854,708
-12% -$31.4M
SEPN
2
Septerna Inc
SEPN
$1.84B
$208M 41.78%
6,215,591
– –
MAZE
3
Maze Therapeutics
MAZE
$1.38B
$28.4M 5.69%
950,800
– –

Similar funds

MA
Mezzasalma Advisors Tinton Falls, New Jersey $498M AUM 56.57% 1-Year Est. Return
GWM
GSB Wealth Management Guilford, Connecticut $498M AUM 27.51% 1-Year Est. Return
CMAI
Capital Management Associates Inc Minneapolis, Minnesota $498M AUM 26.46% 1-Year Est. Return
CWAF
Core Wealth Advisors (Florida) Lakeland, Florida $497M AUM 20.85% 1-Year Est. Return
BRCM
Bright Rock Capital Management Hanover, Massachusetts $499M AUM 8.36% 1-Year Est. Return
TPWM
Twelve Points Wealth Management Concord, Massachusetts $499M AUM 24.01% 1-Year Est. Return
RMAM
Raab & Moskowitz Asset Management Chatham, New Jersey $497M AUM 26.8% 1-Year Est. Return
AFCM
Alta Fox Capital Management Fort Worth, Texas $497M AUM 48.91% 1-Year Est. Return

TRV GP V's Q2 2026 Portfolio in Review

As of Q2 2026, TRV GP V held 3 positions worth $498M, up 24% from $401M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP V withdrew a net $31.4M in Q2 2026, reducing 1 holding. Its largest reduction was Rapport Therapeutics, cutting an estimated $31.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP V's biggest Q2 2026 reduction was Rapport Therapeutics, cutting an estimated $31.4M.
  • TRV GP V's ten largest holdings make up 100% of its $498M portfolio in Q2 2026.
  • TRV GP V opened 0 new positions and closed 0 in Q2 2026.
  • TRV GP V's portfolio value rose 24% quarter-over-quarter to $498M.

Based on TRV GP V's 13F filing for Q2 2026, filed 10 Aug 2026.